scholarly journals Letter by Ianiro et al Regarding Article, “Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium”

Circulation ◽  
2018 ◽  
Vol 137 (2) ◽  
pp. 213-214
Author(s):  
Gianluca Ianiro ◽  
Giovanni Cammarota ◽  
Antonio Gasbarrini
Circulation ◽  
2017 ◽  
Vol 136 (1) ◽  
pp. 52-64 ◽  
Author(s):  
Ronald B. Goldberg ◽  
Vanita R. Aroda ◽  
David A. Bluemke ◽  
Elizabeth Barrett-Connor ◽  
Matthew Budoff ◽  
...  

2016 ◽  
Vol 101 (4) ◽  
pp. 1754-1761 ◽  
Author(s):  
Vanita R. Aroda ◽  
Sharon L. Edelstein ◽  
Ronald B. Goldberg ◽  
William C. Knowler ◽  
Santica M. Marcovina ◽  
...  

Abstract Context: Vitamin B12 deficiency may occur with metformin treatment, but few studies have assessed risk with long-term use. Objective: To assess the risk of B12 deficiency with metformin use in the Diabetes Prevention Program (DPP)/DPP Outcomes Study (DPPOS). Design: Secondary analysis from the DPP/DPPOS. Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin group (MET) (n = 1073) for 3.2 years; subjects in the metformin group received open-label metformin for an additional 9 years. Setting: Twenty-seven study centers in the United States. Patients: DPP eligibility criteria were: elevated fasting glucose, impaired glucose tolerance, and overweight/obesity. The analytic population comprised participants with available stored samples. B12 levels were assessed at 5 years (n = 857, n = 858) and 13 years (n = 756, n = 764) in PLA and MET, respectively. Interventions: Metformin 850 mg twice daily vs placebo (DPP), and open-label metformin in the metformin group (DPPOS). Main Outcome Measures: B12 deficiency, anemia, and peripheral neuropathy. Results: Low B12 (≤ 203 pg/mL) occurred more often in MET than PLA at 5 years (4.3 vs 2.3%; P = .02) but not at 13 years (7.4 vs 5.4%; P = .12). Combined low and borderline-low B12 (≤ 298 pg/mL) was more common in MET at 5 years (19.1 vs 9.5%; P < .01) and 13 years (20.3 vs 15.6%; P = .02). Years of metformin use were associated with increased risk of B12 deficiency (odds ratio, B12 deficiency/year metformin use, 1.13; 95% confidence interval, 1.06–1.20). Anemia prevalence was higher in MET, but did not differ by B12 status. Neuropathy prevalence was higher in MET with low B12 levels. Conclusions: Long-term use of metformin in DPPOS was associated with biochemical B12 deficiency and anemia. Routine testing of vitamin B12 levels in metformin-treated patients should be considered.


2019 ◽  
Vol 7 ◽  
pp. 205031211984198 ◽  
Author(s):  
Pallavi Srivastava ◽  
Ashish Verma ◽  
Christine Geronimo ◽  
Terry M Button

Introduction: Centers for Disease Control and Prevention Diabetes Prevention Program recognition requires successful program completion by a cohort of at least five people with prediabetes. Such programs have generally been “in-person” and provided by a qualified coach from a recognized program. A cohort of 10 patients with prediabetes was enrolled in a physician’s office to use the cloud-based Type II Diabetes Prevention Module in an effort to achieve recognition. Module use was supported by the physician and a qualified coach. The purpose of this article is to evaluate Module performance relative to behavior stages associated with long-term behavior modification. Methods: The Module employs a web application supporting diabetes prevention education and a mobile application that is an electronic diary and virtual coach. A dashboard allows an efficient review of user performance and the ability to send users notifications of support from the user’s coach or physician. The cohort of 10 patients with prediabetes was offered Module use upon diagnosis of prediabetes. Results: All 10 patients with prediabetes offered Module use agreed participation. Six have completed educational sessions, made diary entries, and have met the 5% Centers for Disease Control and Prevention Diabetes Prevention Program weight loss target prior to 6 months of Module use. This high success rate (60%) is contrary to behavior stages often associated with long-term behavior modification. Conclusion: The strength of the physician–patient relationship appears to allow patients with prediabetes to skip or advance rapidly through behavioral stages in the process of lifestyle modification.


2012 ◽  
Vol 303 (2) ◽  
pp. E200-E212 ◽  
Author(s):  
Thomas Hardy ◽  
Eyas Abu-Raddad ◽  
Niels Porksen ◽  
Andrea De Gaetano

The seminal publication of the Diabetes Prevention Program (DPP) results in 2002 has provided insight into the impact of major therapies on the development of diabetes over a time span of a few years. In the present work, the publicly available DPP data set is used to calibrate and evaluate a recently developed mechanistic mathematical model for the long-term development of diabetes to assess the model's ability to predict the natural history of disease progression and the effectiveness of preventive interventions. A general population is generated from which virtual subject samples corresponding to the DPP enrollment criteria are selected. The model is able to reproduce with good fidelity the observed time courses of both diabetes incidence and average glycemia, under realistic hypotheses on evolution of disease and efficacy of the studied therapies, for all treatment arms. Model-based simulations of the long-term evolution of the disease are consistent with the transient benefits observed with conventional therapies and with promising effects of radical improvement of insulin sensitivity (as by metabolic surgery) or of β-cell protection. The mechanistic diabetes progression model provides a credible tool by which long-term implications of antidiabetic interventions can be evaluated.


2014 ◽  
Vol 31 (12) ◽  
pp. 1631-1642 ◽  
Author(s):  
L. M. Jaacks ◽  
Y. Ma ◽  
N. Davis ◽  
L. M. Delahanty ◽  
E. J. Mayer-Davis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document